Ann: Proteomics International seeks FDA approval for PromarkerD, page-178

A nice write up on the support from one of Australia's leading small cap fund managers:

Altor Capital has high conviction on these 4 medtech plays for 2021
Health & Biotech
February 23, 2021 | Derek Rose

Brisbane-based Altor Capital portfolio manager David McNamee specialises in investing in emerging companies with a market capitalisation under $200 million.
He first got into Pointerra (ASX:3DP) at 2c a share, picking it before legendary small-cap investor Bevan Slattery bought in, and invested in Intellihr (ASX:IHR) when it was 3c.
Shares in those companies closed yesterday at 82c and 46c, respectively.
McNamee has also done well with an investment in Rent.com.au (ASX:RNT). He again got in before Slattery invested in the online property marketplace a few weeks ago, sending its shares jumping from around 5c to 24c.
Alas, McNamee’s Alpha Fund is not open to mere mortals – just sophisticated and professional investors. But he’s willing to share with * readers four companies in the medical technology/life sciences space he’s particularly keen on.



Proteomics International Laboratories (ASXIQ)

Proteomics is striving for regulatory approval of its simple, low-cost blood test for chronic kidney disease in patients with type 2 diabetes.
Using a unique protein “fingerprint”, the PromarkerD test can predict the onset of diabetic kidney disease up to four years before symptoms arise with 86 per cent accuracy.
The test has received a CE Mark in Europe and this month the company sent a pre-submission package to the US Food and Drug Administration in advance of a meeting on possible approval.
“They’re in a similar boat, we think they’ve de-risked the health, it’s taken them 20 years to get them to the point where they’ve got a scalable test kit where the three biomarkers line up,” McNamee said.
“And we feel like they’re cusp of commercialising that technology that has been validated by one of the largest pharma groups in the world, by integrating all their clinical data,” McNamee said, referring to Janssen, a subsidiary of Johnson & Johnson.
Proteomics has clinical trials to validate the test that are due probably around the end of March, and is deep in discussions about getting a US manufacturing partner to help the scale-up of their test kits, McNamee said.
Identifying what diabetic patients are at risk of kidney failure opens up a lot of commercial possibilities for large pharmaceutical companies, McNamee said.
The know-how Proteomics developed in working on biomarkers for this test kit should help them as they develop biomarkers for tests for other conditions such as endometriosis, he said.
“So we like that one, there’s a lot of catalysts we feel for this year,” he said.

https://unauthorised investment adv...conviction-on-these-4-medtech-plays-for-2021/